Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular determinants of hERG potassium channel inhibition by disopyramide.

Journal of molecular and cellular cardiology - 1 Jan 2012

El Harchi Aziza, Zhang Yi H, Hussein Leyla, Dempsey Christopher E, Hancox Jules C

Abstract excerpt

The Class Ia antiarrhythmic drug disopyramide (DISO) causes QT interval prolongation that is potentially dangerous in acquired Long QT Syndrome but beneficial in short QT syndrome, through inhibition of the hERG-encoded channels responsible for rapid delayed rectifier K(+) current (I(Kr)). In this study, alanine mutants of hERG S6 and pore helix residues and MthK-based homology modelling and ligand docking were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Action Potentials
Share to Anti-Arrhythmia Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to ERG1 Potassium Channel

Share to Ether-A-Go-Go Potassium Channels

Share to HEK293 Cells

Share to Models, Molecular

Share to Protein Conformation

Source

Identifiers

PMID: 21989164
DOI: 10.1016/j.yjmcc.2011.09.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular determinants of hERG potassium channel inhibition by disopyramide.PMID 21989164Read ↗

Stereoselective block of the hERG potassium channel by the Class Ia antiarrhythmic drug disopyramide.Semantic proximity Read ↗

Structural determinants for high-affinity block of hERG potassium channels.Semantic proximity Read ↗

Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.Semantic proximity Read ↗

The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.Semantic proximity Read ↗

Stereoselective block of the hERG potassium channel by the Class Ia antiarrhythmic drug disopyramide.Semantic proximity Read ↗

Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.Semantic proximity Read ↗

Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.Semantic proximity Read ↗

Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome.Semantic proximity Read ↗

Molecular Basis for state-dependent drug block of Kv11.1 (HERG) potassium channelsSemantic proximity Read ↗

Lidoflazine is a high affinity blocker of the HERG K(+)channel.Semantic proximity Read ↗

hERG potassium channels and cardiac arrhythmia.Semantic proximity Read ↗

Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.